基于列线图风险分层评估在pT1-2N1M0乳腺癌患者术后放疗决策中的意义
回顾性分析936例pT1-2N1M0乳腺癌根治术后患者,583例接受术后放疗(PMRT)、325例未接受,中位随访98个月,PSM后比较OS和DFS。PMRT组5年和8年OS及DFS均显著优于未放疗组(P<0.001)。列线图显示高危组PMRT显著改善OS(P=0.001),中危和高危组DFS显著改善(P=0.036、P=0.001),低危组无显著获益。
要点
- 年龄≤40岁、内象限或中央区肿瘤、T2期、2-3枚淋巴结转移、Ki67>30%为影响预后的高危因素。
- OS列线图风险评分≥149分者接受PMRT后OS改善;DFS列线图风险评分≥123分者接受PMRT后DFS改善。
- PMRT组5年和8年OS及DFS均显著优于未放疗组(P<0.001)。
核心结论
- 年龄≤40岁、肿瘤位于内象限或中央区、T2期、2-3枚淋巴结转移、Ki67>30%是影响该队列患者预后的高危因素。
- OS列线图风险评分≥149分的患者接受PMRT后OS改善;DFS列线图风险评分≥123分的患者接受PMRT后DFS改善。
研究设计与样本
- 回顾性分析2010至2016年河北医科大学第四医院936例pT1-2N1M0乳腺癌根治术后患者临床数据,其中583例接受PMRT、325例未接受PMRT。
- 采用倾向性评分匹配(PSM)方法减轻组间不均衡,用log-rank检验比较队列间总生存(OS)和无病生存(DFS)。
- 利用列线图模型评估PMRT在不同风险组中的疗效。
主要发现
- 中位随访98个月,接受PMRT患者5年和8年OS及DFS较未接受PMRT者显著改善(P<0.001)。
- 多因素分析显示年龄、原发肿瘤部位、阳性淋巴结、分期和Ki-67水平独立影响OS,年龄、原发肿瘤部位和分期独立影响DFS。
- PMRT显著改善高危组OS(P=0.001),低危组和中危组未获益(P=0.057、P=0.099)。
- PMRT使中危组和高危组DFS显著改善(P=0.036、P=0.001),低危组未获显著获益(P=0.475)。
关键数值与推荐
- OS列线图风险评分≥149分者接受PMRT后OS改善。
- DFS列线图风险评分≥123分者接受PMRT后DFS改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To explore the high-risk factors affecting the prognosis of pT1 - 2N1M0 patients after mastectomy, establish a nomogram prediction model, and screen the radiotherapy benefit population. METHOD: The clinical data of 936 patients with pT1 - 2N1M0 who underwent mastectomy in the fourth hospital of Hebei Medical University from 2010 to 2016 were retrospectively analyzed. There were 583 patients received postmastectomy radiotherapy(PMRT), and 325 patients without PMRT. Group imbalances were mitigated using the propensity score matching (PSM) method, and the log-rank test was employed to compare overall survival (OS) and disease-free survival (DFS) between the cohorts. The efficacy of PMRT across various risk groups was evaluated using a nomogram model. RESULT: The median follow-up period was 98 months, Patients who received PMRT demonstrated significantly improved 5-year and 8-year OS and DFS compared to those who did not (P < 0.001). Multivariate analysis revealed that age, primary tumor site, positive lymph node, stage, and Ki-67 level independently influenced OS, while age, primary tumor site, and stage independently affected DFS. PMRT drastically enhanced OS in the high-risk group (P = 0.001), but did not confer benefits in the low-risk and intermediate risk groups (P = 0.057, P = 0.099). PMRT led to a significant improvement in disease-free survival (DFS) among patients in the intermediate and high-risk groups (P = 0.036, P = 0.001), whereas the low-risk group did not experience a significant benefit (P = 0.475). CONCLUSION: Age ≤ 40 years, tumor located in the inner quadrant or central area, T2 stage, 2-3 lymph nodes metastasis, and Ki67 > 30% were the high-risk factors affecting the prognosis of this cohort of patients. In OS nomogram, patients with a risk score of 149 or higher who received PMRT exhibited improved OS. Similarly, in DFS nomogram, patients with a risk score of 123 or higher who received PMRT demonstrated enhanced DFS.
引用
- Wei C, Kong J, Han H, et al. The significance of risk stratification through nomogram-based assessment in determining postmastectomy radiotherapy for patients diagnosed with pT1 - 2N1M0 breast cancer. Radiat Oncol. 2024. PMID: 39272162. doi:10.1186/s13014-024-02510-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。